<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Thiazides versus loop diuretics in the treatment of hypertension
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Thiazides versus loop diuretics in the treatment of hypertension
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Thiazides versus loop diuretics in the treatment of hypertension
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rajiv Agarwal, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George L Bakris, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 04, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H4223537744">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diuretics, particularly thiazide-type and thiazide-like diuretics, are commonly used in the treatment of hypertension. Diuretics lower the blood pressure, at least initially, by inducing sodium and fluid loss.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3860.html" rel="external">
          "Use of thiazide diuretics in patients with primary (essential) hypertension"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2338.html" rel="external">
          "Mechanism of action of diuretics"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Loop diuretics are commonly used to treat edematous states. (See
         <a class="medical medical_review" href="/z/d/html/6884.html" rel="external">
          "General principles of the treatment of edema in adults"
         </a>
         .)
        </p>
        <p>
         The major differences between thiazide and loop diuretics in the treatment of hypertension are discussed in this topic. The mechanism of action and side effects of diuretics, and different effects of thiazide and loop diuretics on calcium balance, are discussed in detail elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2338.html" rel="external">
          "Mechanism of action of diuretics"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3860.html" rel="external">
          "Use of thiazide diuretics in patients with primary (essential) hypertension", section on 'Side effects'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">
          "Loop diuretics: Dosing and major side effects", section on 'Major side effects'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2356.html" rel="external">
          "Time course of loop and thiazide diuretic-induced electrolyte complications"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2380.html" rel="external">
          "Diuretic-induced hyperuricemia and gout"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2340.html" rel="external">
          "Diuretics and calcium balance"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1">
         <span class="h1">
          ANTIHYPERTENSIVE DIFFERENCES BETWEEN THIAZIDE AND LOOP DIURETICS
         </span>
        </p>
        <p class="headingAnchor" id="H297336356">
         <span class="h2">
          Patients without chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         When used in patients with primary hypertension and relatively normal kidney function, the thiazide diuretics, particularly
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         and
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         , are more effective antihypertensive drugs than the loop diuretics [
         <a href="#rid1">
          1-6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3860.html" rel="external">
          "Use of thiazide diuretics in patients with primary (essential) hypertension"
         </a>
         .)
        </p>
        <p>
         The difference in efficacy is probably related to duration of action of these diuretics [
         <a href="#rid4">
          4
         </a>
         ]. Commonly used loop diuretics, such as
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         and
         <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">
          bumetanide
         </a>
         , have a short duration of action (less than six hours); the antihypertensive efficacy of these medications may be limited since the initial fluid loss can be counteracted by activation of the renin-angiotensin-aldosterone system, leading to sodium retention during the period when the diuretic effect has worn off [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Longer-acting loop diuretics are available;
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         , for example, has a duration of action up to 12 hours. In a blinded, randomized trial,
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         , given twice daily, and torsemide, given once daily, produced similar systolic pressure reductions in patients with chronic kidney disease (CKD) [
         <a href="#rid8">
          8
         </a>
         ]. Thus, once-daily torsemide appears to be as effective as an equivalent dose of twice-daily furosemide in reducing blood pressure. Whether torsemide is as effective an antihypertensive agent as thiazide diuretics is unknown.
        </p>
        <p class="headingAnchor" id="H2615082471">
         <span class="h2">
          Patients with chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is a commonly held belief that the above observations do not necessarily apply to patients with CKD and that thiazide diuretics are less effective in such patients. However, several studies indicate that thiazide diuretics are effective in such patients.
        </p>
        <p>
         All diuretics are less effective in patients with impaired kidney function. Both thiazide and loop diuretics must reach the lumen of the renal tubule to act, a process mediated by organic acid transporters in the proximal tubule [
         <a href="#rid9">
          9
         </a>
         ]. As glomerular filtration rate (GFR) decreases, organic acid levels increase, and these acids compete with diuretics for transport into the tubular lumen. Thiazides are less effective in competing with accumulating organic acids than loop diuretics in this setting [
         <a href="#rid9">
          9
         </a>
         ]. Thiazide diuretics are therefore considered by many to be less effective in patients with a GFR less than 30 mL/min [
         <a href="#rid10">
          10
         </a>
         ]. Because fluid retention is thought to play a major role in the elevation in blood pressure in CKD, such patients are often prescribed loop diuretics as antihypertensive agents, rather than thiazide diuretics. (See
         <a class="medical medical_review" href="/z/d/html/3872.html" rel="external">
          "Overview of hypertension in acute and chronic kidney disease"
         </a>
         .)
        </p>
        <p>
         However, several interventional studies suggest that thiazides are effective even among patients with advanced CKD [
         <a href="#rid11">
          11-15
         </a>
         ]. The following examples illustrate the range of findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The best data come from a blinded trial of 160 patients with advanced CKD (estimated GFR [eGFR] 15 to 29 mL/min/1.73 m
         <sup>
          2
         </sup>
         ) and uncontrolled hypertension (defined as 24-hour ambulatory blood pressure ≥130 mmHg systolic or ≥80 mmHg diastolic) despite antihypertensive therapy including an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), or a beta blocker [
         <a href="#rid15">
          15
         </a>
         ]. Patients were randomly assigned to
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         , 12.5 mg daily titrated to a maximum of 50 mg daily, or placebo. At 12 weeks, the decrease in 24-hour ambulatory systolic pressure was greater in the chlorthalidone group (by 11.0 versus 0.5 mmHg); ambulatory diastolic pressure also declined (by 4.9 versus 1.0 mmHg). Chlorthalidone led to a reduction in urine albumin-to-creatinine ratio and a reversible reduction in eGFR, which was larger among patients who were also taking a loop diuretic. Hypokalemia (10 versus 0 percent), hyponatremia (11 versus 8 percent), and dizziness (25 versus 16 percent) were more common with chlorthalidone. Serious adverse events leading to hospitalization occurred in eight patients assigned to chlorthalidone and 11 patients assigned to placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Previous, smaller studies yielded similar findings:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A blinded, randomized, crossover trial of 23 patients with hypertension and an eGFR &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         compared
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         (60 mg/day) with
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         (25 mg/day), each for three months [
         <a href="#rid12">
          12
         </a>
         ]. The effects on blood pressure were similar; mean arterial pressure decreased from 101 to 93 mmHg with furosemide and to 94 mmHg with hydrochlorothiazide. Patients were then placed on a combination of the two drugs, which produced an even greater antihypertensive effect, although with more adverse metabolic consequences. (See
         <a class="medical medical_review" href="/z/d/html/3860.html" rel="external">
          "Use of thiazide diuretics in patients with primary (essential) hypertension", section on 'Side effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">
          "Loop diuretics: Dosing and major side effects", section on 'Major side effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2380.html" rel="external">
          "Diuretic-induced hyperuricemia and gout"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In another study of 60 patients with normal kidney function and 60 patients with CKD (mean eGFR 39 mL/min/1.73 m
         <sup>
          2
         </sup>
         ), 25 mg/day of
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         for eight weeks lowered blood pressure to a similar degree in both groups (by 20/9 and 23/10 mmHg) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          OTHER DIURETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The potassium-sparing agents
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          triamterene
         </a>
         and
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         have a minimal antihypertensive effect and are not widely used as initial therapy for primary hypertension [
         <a href="#rid16">
          16
         </a>
         ], although amiloride may be valuable in treating resistant hypertension [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         By comparison, the mineralocorticoid receptor antagonists
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         (with which there is the widest experience as monotherapy) and
         <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">
          eplerenone
         </a>
         are more potent antihypertensive agents. In view of their apparent ability to reduce cardiac and kidney fibrosis [
         <a href="#rid18">
          18
         </a>
         ], aldosterone antagonists have become widely used [
         <a href="#rid19">
          19,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3838.html" rel="external">
          "Treatment of hypertension in patients with heart failure"
         </a>
         .)
        </p>
        <p>
         Mineralocorticoid receptor antagonists are also preferred agents in patients with resistant hypertension. This issue is discussed in detail elsewhere.
        </p>
        <p class="headingAnchor" id="H2332862413">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109601.html" rel="external">
          "Society guideline links: Hypertension in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diuretics lower the blood pressure by inducing sodium and fluid loss. (See
         <a class="medical medical_review" href="/z/d/html/3860.html" rel="external">
          "Use of thiazide diuretics in patients with primary (essential) hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2338.html" rel="external">
          "Mechanism of action of diuretics"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients with normal kidney function, thiazide diuretics, particularly
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         and
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         , have a greater antihypertensive effect than the loop diuretics. This may be related to the longer duration of action of thiazide compared with most loop diuretics. (See
         <a class="local">
          'Patients without chronic kidney disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although it is a commonly held belief that thiazide diuretics are not effective antihypertensive agents in patients with chronic kidney disease (CKD), they appear to be as effective as loop diuretics in such patients. (See
         <a class="local">
          'Patients with chronic kidney disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4131100505">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Norman Kaplan, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Araoye MA, Chang MY, Khatri IM, Freis ED. Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. JAMA 1978; 240:1863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland OB, Gomez-Sanchez CE, Kuhnert LV, et al. Antihypertensive comparison of furosemide with hydrochlorothiazide for black patients. Arch Intern Med 1979; 139:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finnerty FA Jr, Maxwell MH, Lunn J, Moser M. Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension a two-year comparison of efficacy and safety. Angiology 1977; 28:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan NM. The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide. Hypertension 2009; 54:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roush GC, Ernst ME, Kostis JB, et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 2015; 65:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly RA, Wilcox CS, Mitch WE, et al. Response of the kidney to furosemide. II. Effect of captopril on sodium balance. Kidney Int 1983; 24:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasavada N, Saha C, Agarwal R. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int 2003; 64:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brater DC. Pharmacology of diuretics. Am J Med Sci 2000; 319:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           REUBI FC, COTTIER PT. Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation 1961; 23:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinha AD, Agarwal R. Thiazides are useful agents in CKD. J Am Soc Hypertens 2016; 10:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dussol B, Moussi-Frances J, Morange S, et al. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich) 2012; 14:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol 2014; 39:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cirillo M, Marcarelli F, Mele AA, et al. Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function. Hypertension 2014; 63:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med 2021; 385:2507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heran BS, Chen JM, Wang JJ, Wright JM. Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension. Cochrane Database Syst Rev 2012; 11:CD008167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuster GM, Kotlyar E, Rude MK, et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005; 111:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005; 18:50.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3871 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/357764" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/383033" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Antihypertensive comparison of furosemide with hydrochlorothiazide for black patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/869273" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension a two-year comparison of efficacy and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19752290" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21383313" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25733245" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6355617" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Response of the kidney to furosemide. II. Effect of captopril on sodium balance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12846760" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10653443" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pharmacology of diuretics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13740990" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26987648" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Thiazides are useful agents in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22235821" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24526255" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24396024" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34739197" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23152254" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16116042" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15687129" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12682082" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15691617" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
